Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies

References

• Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163–173. doi: 10.1001/jamacardio.2018.4537.
   PubMed Web of Science ®Google Scholar
• Kim TH, Yang PS, Yu HT, et al. Age threshold for ischemic stroke risk in atrial fibrillation. Stroke. 2018;49(8):1872–1879. doi: 10.1161/STROKEAHA.118.021047.
   PubMed Web of Science ®Google Scholar
• Mitrousi K, Lip GYH, Apostolakis S. Age as a risk factor for stroke in atrial fibrillation patients: implications in thromboprophylaxis in the era of novel oral anticoagulants. J Atr Fibrillation. 2013;6(1):783. doi: 10.4022/jafib.783.
   PubMedGoogle Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130(2):138–146. doi: 10.1161/CIRCULATIONAHA.113.005008.
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21. doi: 10.1186/1477-9560-11-21.
   PubMedGoogle Scholar
• Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized Real-World evidence studies. Circulation. 2021;143(10):1002–1013. doi: 10.1161/CIRCULATIONAHA.120.051718.
   PubMed Web of Science ®Google Scholar
• Wang SV, Schneeweiss S, Franklin JM, RCT-DUPLICATE Initiative., et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023;329(16):1376–1385. doi: 10.1001/jama.2023.4221.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care. 2010;16(6):467–471.
   PubMed Web of Science ®Google Scholar
• Weeda ER, Nguyen E, Martin S, et al. The impact of non-medical switching among ambulatory patients: an updated systematic literature review. J Mark Access Health Policy. 2019;7(1):1678563. doi: 10.1080/20016689.2019.1678563.
   PubMedGoogle Scholar
• Alcusky M, Tjia J, McManus DD, et al. Comparative safety and effectiveness of direct-acting oral anticoagulants versus warfarin: a national cohort study of nursing home residents. J Gen Intern Med. 2020;35(8):2329–2337. doi: 10.1007/s11606-020-05777-3.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595–1604. doi: 10.1080/03007995.2017.1345729.
   Google Scholar
• Amin A, Keshishian A, Dina O, et al. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis. 2019;48(2):240–249. doi: 10.1007/s11239-019-01838-5.
   PubMed Web of Science ®Google Scholar
• Amin A, Garcia Reeves AB, Li X, et al. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS One. 2019;14(3):e0213614. doi: 10.1371/journal.pone.0213614.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Hines DM, et al. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis. Curr Med Res Opin. 2022;38(12):2131–2140. doi: 10.1080/03007995.2022.2115772.
   Google Scholar
• Briasoulis A, Inampudi C, Akintoye E, et al. Safety and efficacy of novel oral anticoagulants versus warfarin in Medicare beneficiaries with atrial fibrillation and valvular heart disease. J Am Heart Assoc. 2018;7(8):e008773. doi: 10.1161/JAHA.118.008773.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Turpie AGG, Bunz TJ, et al. Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism. Am J Med. 2018;131(8):933–938.e1. doi: 10.1016/j.amjmed.2018.02.015.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Weeda ER, Nguyen E, et al. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018;4(4):328–329. doi: 10.1093/ehjqcco/qcx044.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Baker WL, Meinecke AK, et al. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):159–166. doi: 10.1093/ehjcvp/pvz047.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Costa OS, Brescia CW, et al. A RIVA-DM subanalysis investigating patients with nonvalvular atrial fibrillation and type 2 diabetes aged under versus over 80 years. Clin Appl Thromb Hemost. 2022;28:10760296221133083. doi: 10.1177/10760296221133083.
   Web of Science ®Google Scholar
• Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. J Thromb Thrombolysis. 2021;51(2):349–358. doi: 10.1007/s11239-020-02199-0.
   PubMed Web of Science ®Google Scholar
• Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin. 2020;36(7):1081–1088. doi: 10.1080/03007995.2020.1762554.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Keshishian A, Li X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc. 2019;67(8):1662–1671. doi: 10.1111/jgs.15956.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11. doi: 10.1016/j.amjmed.2018.12.023.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017;120(10):1813–1819. doi: 10.1016/j.amjcard.2017.07.092.
   PubMed Web of Science ®Google Scholar
• Kim DH, Pawar A, Gagne JJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation : a cohort study. Ann Intern Med. 2021;174(9):1214–1223. doi: 10.7326/M20-7141.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944. doi: 10.1161/STROKEAHA.118.020232.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021;289(1):42–52. doi: 10.1111/joim.13140.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Norby FL, Zakai NA, et al. Oral anticoagulation therapy and subsequent risk of vnous thromboembolism in atrial fibrillation patients. Curr Med Res Opin. 2019;35(5):837–845. doi: 10.1080/03007995.2018.1541445.
   PubMed Web of Science ®Google Scholar
• Martinez BK, Sood NA, Bunz TJ, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(8):e008643. doi: 10.1161/JAHA.118.008643.
   PubMed Web of Science ®Google Scholar
• Mehta HB, An H, Ardeshirrouhanifard S, et al. Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among adults with cancer and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2022;15(12):e008951. doi: 10.1161/CIRCOUTCOMES.122.008951.
   PubMed Web of Science ®Google Scholar
• Mentias A, Heller E, Vaughan Sarrazin M. Comparative effectiveness of rivaroxaban, apixaban, and warfarin in atrial fibrillation patients with polypharmacy. Stroke. 2020;51(7):2076–2086. doi: 10.1161/STROKEAHA.120.029541.
   PubMed Web of Science ®Google Scholar
• Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2017;17(1):238. doi: 10.1186/s12872-017-0672-5.
   PubMedGoogle Scholar
• Pawar A, Gagne JJ, Gopalakrishnan C, et al. Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization for venous thromboembolism. JAMA. 2022;327(11):1051–1060. doi: 10.1001/jama.2022.1920.
   PubMed Web of Science ®Google Scholar
• Palamaner Subash Shantha G, Bhave PD, Girotra S, et al. Sex-Specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2017;10(4):e003418. doi: 10.1161/CIRCOUTCOMES.116.003418.
   PubMed Web of Science ®Google Scholar
• Sood N, Ashton V, Bessada Y, et al. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with concomitant obstructive sleep apnea. TH Open. 2023;7(1):e82–e93. doi: 10.1055/a-2013-3346.
   PubMedGoogle Scholar
• Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J. 2020;223:3–11. doi: 10.1016/j.ahj.2020.01.010.
   PubMed Web of Science ®Google Scholar
• Wong JM, Maddox TM, Kennedy K, et al. Comparing major bleeding risk in outpatients with atrial fibrillation or flutter by oral anticoagulant type (from the national cardiovascular disease registry’s practice innovation and clinical excellence registry). Am J Cardiol. 2020;125(10):1500–1507. doi: 10.1016/j.amjcard.2020.02.028.
   PubMed Web of Science ®Google Scholar
• Zakai NA, Walker RF, MacLehose RF, et al. Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis. Res Pract Thromb Haemost. 2021;5(6):e12575. doi: 10.1002/rth2.12575.
   PubMed Web of Science ®Google Scholar
• Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718. doi: 10.1161/JAHA.113.000718.
   PubMed Web of Science ®Google Scholar
• Doni K, Bühn S, Weise A, et al. Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials. Geroscience. 2023; doi: 10.1007/s11357-023-00825-2.
   PubMed Web of Science ®Google Scholar
• Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39(7):1456–1478.e36. doi: 10.1016/j.clinthera.2017.05.358.
   PubMed Web of Science ®Google Scholar
• Briere JB, Bowrin K, Millier A, et al. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. J Med Econ. 2019;22(8):760–765. doi: 10.1080/13696998.2019.1606001.
   PubMed Web of Science ®Google Scholar
• Mittal VS, Wu B, Song J, et al. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study. Curr Med Res Opin. 2020;36(4):529–536. doi: 10.1080/03007995.2019.1706464.
   PubMed Web of Science ®Google Scholar
• Mahajan D, Wu B, Song J, et al. Comparison of healthcare resource utilization and costs between rivaroxaban and warfarin for nonvalvular atrial fibrillation in a skilled nursing facility setting. Drugs Aging. 2020;37(4):281–289. doi: 10.1007/s40266-019-00737-x.
   PubMed Web of Science ®Google Scholar